Literature DB >> 20387310

Biomarkers in systemic sclerosis.

Susan V Castro1, Sergio A Jimenez.   

Abstract

Systemic sclerosis is an autoimmune inflammatory disorder of unknown etiologycharacterized b y pronounced fibroproliferative alterations in the microvasculature, and frequent cellular and humoral immunity abnormalities, culminating in a severe and often progressive fibrotic process. Numerous biomarkers reflecting the three main pathogenetic mechanisms in systemic sclerosis have been described; however, aside from several disease-specific autoantibodies, other biomarkers have not been thoroughly validated and require further study. Thus, there is an unmet need for validated biomarkers for diagnosis, disease classification, and evaluation of organ involvement and therapeutic response in systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20387310      PMCID: PMC3049114          DOI: 10.2217/bmm.09.79

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  120 in total

1.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages.

Authors:  B M Kräling; G G Maul; S A Jimenez
Journal:  Pathobiology       Date:  1995       Impact factor: 4.342

2.  Soluble serum interleukin 2 receptors in patients with systemic sclerosis.

Authors:  V D Steen; E E Engel; M R Charley; T A Medsger
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

3.  Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis.

Authors:  H Ihn; S Sato; M Fujimoto; K Takehara; K Tamaki
Journal:  Br J Rheumatol       Date:  1998-11

Review 4.  Immunopathogenesis of systemic sclerosis.

Authors:  B White
Journal:  Rheum Dis Clin North Am       Date:  1996-11       Impact factor: 2.670

5.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

6.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Authors:  D J Abraham; R Vancheeswaran; M R Dashwood; V S Rajkumar; P Pantelides; S W Xu; R M du Bois; C M Black
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

7.  In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.

Authors:  M S Gruschwitz; M Albrecht; G Vieth; U F Haustein
Journal:  J Rheumatol       Date:  1997-10       Impact factor: 4.666

8.  Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.

Authors:  C P Denton; M C Bickerstaff; X Shiwen; M T Carulli; D O Haskard; R M Dubois; C M Black
Journal:  Br J Rheumatol       Date:  1995-11

9.  Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity.

Authors:  M S Gruschwitz; O P Hornstein; P von Den Driesch
Journal:  Arthritis Rheum       Date:  1995-02

10.  Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis.

Authors:  A D Blann; A Herrick; M I Jayson
Journal:  Br J Rheumatol       Date:  1995-09
View more
  19 in total

1.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 2.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 3.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

4.  Rapid, noninvasive quantitation of skin disease in systemic sclerosis using optical coherence elastography.

Authors:  Yong Du; Chih-Hao Liu; Ling Lei; Manmohan Singh; Jiasong Li; M John Hicks; Kirill V Larin; Chandra Mohan
Journal:  J Biomed Opt       Date:  2016-04-30       Impact factor: 3.170

Review 5.  Quantitating skin fibrosis: innovative strategies and their clinical implications.

Authors:  Giuseppina Abignano; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

6.  Translational optical coherence elastography for assessment of systemic sclerosis.

Authors:  Chih-Hao Liu; Shervin Assassi; Sam Theodore; Christopher Smith; Alexander Schill; Manmohan Singh; Salavat Aglyamov; Chandra Mohan; Kirill V Larin
Journal:  J Biophotonics       Date:  2019-08-08       Impact factor: 3.207

7.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

8.  Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction.

Authors:  Tracy Frech; Ashley E Walker; Zachary Barrett-O'Keefe; Paul N Hopkins; Russell S Richardson; D Walter Wray; Anthony J Donato
Journal:  Clin Rheumatol       Date:  2014-12-16       Impact factor: 2.980

9.  Serum galectin-3 level in systemic sclerosis.

Authors:  Suleyman Serdar Koca; Fatma Akbas; Metin Ozgen; Servet Yolbas; Nevin Ilhan; Baris Gundogdu; Ahmet Isik
Journal:  Clin Rheumatol       Date:  2013-08-03       Impact factor: 2.980

10.  Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.

Authors:  Julien Guiot; Makon-Sébastien Njock; Béatrice André; Fanny Gester; Monique Henket; Dominique de Seny; Catherine Moermans; Michel G Malaise; Renaud Louis
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.